ZIVO · XBRL financial data

Zivo Bioscience financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ZIVO's year ends in late December)

In thousands of dollars	FY 2019Dec 31, 2019	FY 2020Dec 31, 2020	FY 2021†Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024
Revenue	0	20	0	0	28	157
Revenue from contracts with customers	—	—	—	0	28	157
Cost of goods and services sold	—	—	—	0	16	108
Gross profit	—	—	—	0	12	49
Research and development	2,307	3,755	2,120	2,240	1,377	3,135
General and administrative	4,076	1,948	6,933	6,492	5,898	10,276
Total operating expenses	8,352	8,576	9,053	8,732	7,275	13,411
Operating income (loss)	(8,352)	(8,556)	(9,053)	(8,732)	(7,263)	(13,362)
Interest expense	—	98	45	13	24	—
Net income (loss)	(11,510)	(9,106)	(9,163)	(8,745)	(7,777)	(13,385)
Earnings per share, diluted USD per share	—	—	—	—	(4.60)	(4.23)
Weighted average shares, diluted thousands of shares	—	—	—	—	1,690	3,167

† Share count changed about 1/44 in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (ZIVO's year ends in late December)

In thousands of dollars	FY 2019Dec 31, 2019	FY 2020Dec 31, 2020	FY 2021†Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024
Cash and cash equivalents	346	138	8,902	1,799	274	1,542
Accounts receivable	0	—	—	—	—	—
Prepaid and other current assets	23	30	58	102	147	91
Total current assets	369	168	8,960	1,902	425	1,635
Property and equipment, net	0	0	0	0	0	—
Right-of-use asset	0	49	27	189	98	0
Total assets	369	220	8,990	2,123	556	1,643
Accounts payable	1,372	1,560	654	491	993	547
Accrued liabilities	103	214	467	398	1,149	1,096
Total current liabilities	8,708	11,394	2,948	2,028	2,762	2,042
Lease liability, non-current	0	15	0	106	0	116
Total liabilities	8,708	11,531	2,948	2,134	2,762	2,158
Accumulated deficit	(89,958)	(99,064)	(108,227)	(115,805)	(123,582)	(136,967)
Total stockholders' equity	(8,338)	(11,311)	6,042	(11)	(2,206)	(515)
Total liabilities and equity	369	220	8,990	2,123	556	1,643
Common shares outstanding (cover page) thousands of shares	402,199	418,346	9,420	9,420	2,778	3,759

† Share count changed about 1/44 in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (ZIVO's year ends in late December)

In thousands of dollars	FY 2019Dec 31, 2019	FY 2020Dec 31, 2020	FY 2021†Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024
Net income (loss)	(11,510)	(9,106)	(9,163)	(8,745)	(7,777)	(13,385)
Stock-based compensation	—	—	(105)	298	90	1,511
Net cash from operating activities	(3,707)	(2,588)	(6,803)	(7,103)	(5,800)	(4,314)
Net cash from investing activities	0	0	0	0	0	0
Proceeds from issuing common stock	2,650	401	1,515	0	485	5,602
Proceeds from issuing equity	—	0	50	50	—	—
Net cash from financing activities	3,665	2,380	15,567	0	4,275	5,582

† Share count changed about 1/44 in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Zivo Bioscience	57	66	(267)*	3.9M	0.2 quarters	Q3 FY25 10-QSep 30, 2025
Regen BioPharma	0.2	59	(24)*	1.7B	0.0 quarters	Q3 FY26 10-QJun 30, 2026
One World Products	169	50	(145)*	120.1M	1.2 quarters	Q3 FY25 10-QSep 30, 2025
Yarrow Bioscience	22,925	97	(1,992)*	2.7M	11.5 quarters	Q2 FY26 10-QJun 30, 2026
Cardiff Oncology	9,197	104	(11,765)*	77.8M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Cocrystal Pharma	2,169	105	(2,516)*	19.3M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
Nutra Pharma	not reported	34	(251)*	7.2B	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Parabilis Medicines	1,087,060	148	not reported	121.9M	—	Q2 FY26 10-QJun 30, 2026
Vyome Holdings	7,888	27	(904)*	7.0M	8.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.